FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma

BACKGROUND: Despite the scarcity of data based on randomized trials, FOLFIRINOX is widely used in the management of borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC). We investigated the clinical outcomes of neoadjuvant FOLFIRINOX in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Hwang, Inhwan, Song, Tae Jun, Lee, Sang Soo, Jeong, Jae Ho, Park, Do Hyun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Byun, Jae Ho, Park, Jin-hong, Hwang, Dae Wook, Song, Ki Byung, Lee, Jae Hoon, Lee, Woohyung, Chang, Heung-Moon, Kim, Kyu-pyo, Kim, Song Cheol, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498966/
https://www.ncbi.nlm.nih.gov/pubmed/32983266
http://dx.doi.org/10.1177/1758835920953294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498966/
https://www.ncbi.nlm.nih.gov/pubmed/32983266
http://dx.doi.org/10.1177/1758835920953294

Ejemplares similares